Generic placeholder image

Current Cardiology Reviews

Editor-in-Chief

ISSN (Print): 1573-403X
ISSN (Online): 1875-6557

Trials of Novel Oral Anticoagulants for Stroke Prevention In Patients with Non-valvular Atrial Fibrillation

Author(s): Jonathan L. Halperin and Paul Dorian

Volume 10, Issue 4, 2014

Page: [297 - 302] Pages: 6

DOI: 10.2174/1573403X10666140513104523

Price: $65

Abstract

Patients with non-valvular atrial fibrillation (AF) face an increased risk of stroke compared with those in normal sinus rhythm. The vitamin K antagonist warfarin, available for over half a century, is highly effective in reducing the risk of stroke in patients with AF, but it is a difficult drug to use properly. As a result, it is challenging to keep the anticoagulant effect of warfarin in the desired range. Newer oral anticoagulants (NOACs) that directly inhibit Factor IIa (thrombin) or Factor Xa provide reliable anticoagulation when administer in fixed oral doses without routine coagulation monitoring. This manuscript will review in detail the pivotal trials of these NOACs that led to their approval as well as comment on the factors that should influence their selection.

Keywords: Anticoagulation, antithrombotic therapy, atrial fibrillation, factor IIa inhibitors, factor Xa inhibitors, stroke, thrombin, thromboembolism.


Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy